CSLHAM:CSJ -2.02%73 EV-to-FCF is 79.50 as of Jun. 27, 2026, which is 6% above its 10-year median of 74.80. GuruFocus rates HAM:CSJ with a GF Score™ of 73/100 and a GF Value™ of €171.51 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 333 Biotechnology companies, CSL ranks worse than 86.49% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CSL's Enterprise Value is €43,856 Mil.
CSL's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €552 Mil. Therefore, CSL's EV-to-FCF for today is 79.50.
The historical rank and industry rank for CSL's EV-to-FCF or its related term are showing as below:
HAM:CSJ'
s EV-to-FCF Range Over the Past 10 Years
Min: 16.52 Med: 74.8 Max: 306.33
Current: 74.28
During the past 13 years, the highest EV-to-FCF of CSL was 306.33. The lowest was 16.52. And the median was 74.80.
HAM:CSJ's EV-to-FCF is ranked worse than 86.49% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs HAM:CSJ: 74.28
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-27), CSL's stock price is €70.36.
CSL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.700. Therefore, CSL's PE Ratio (TTM) for today is 100.51.
CSL (HAM:CSJ) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CSL's share price for today is €70.36.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CSL EV-to-FCF Related Terms
CSL EV-to-FCF Historical Data
* Premium members only.
The historical data trend for CSL's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CSL's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where CSL's EV-to-FCF falls into.
CSL's current Enterprise Value is €43,856 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €552 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (HAM:CSJ) has a EV-to-FCF of 79.50 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CSL and its competitors. This is near median its historical median of 74.80. Over the past decade, CSL's EV-to-FCF has ranged from 16.52 to 306.33. According to the industry distribution chart, CSL ranks #288 out of 333 companies in the Biotechnology industry, placing it in the top 86.5%.
Is CSL's EV-to-FCF too high?
CSL's current EV-to-FCF of 79.50 is near median its 10-year median of 74.80. Over the past 10 years, this metric has ranged from a low of 16.52 to a high of 306.33. The Biotechnology industry median EV-to-FCF is 14.65. CSL's value of 79.50 is 442.7% above this industry median. Based on the distribution chart, CSL ranks #288 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #288 out of 333 companies for EV-to-FCF. This places CSL in the lower half of its industry. The industry median EV-to-FCF is 14.65. CSL's value of 79.50 is 442.7% above this benchmark. Historically, CSL's own EV-to-FCF has ranged from 16.52 to 306.33 over the past decade. While the company's 10-year median is 74.80 vs. the industry median of 14.65, CSL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current EV-to-FCF of 79.50 is 442.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CSL and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current EV-to-FCF is 79.50, which is near median its own 10-year median of 74.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (HAM:CSJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €171.51, compared to a current price of €70.36 — trading 59% below its estimated fair value. The current EV-to-FCF is 79.50, which is near median its 10-year median of 74.80 and 442.7% above the Biotechnology industry median of 14.65. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For CSL (HAM:CSJ), the current EV-to-FCF is 79.50 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (HAM:CSJ) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of €70.36 is trading 59% below its estimated GF Value™ of €171.51.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for HAM:CSJ:
EV-to-FCF: 79.50 (near median its 10-year median of 74.80)
GF Value™: €171.51 vs. price of €70.36 (59% below fair value)
Industry Position: 442.7% above the Biotechnology median (#288 of 333)
No single metric tells the full story. See the HAM:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for HAM:CSJ
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:CSJ has been successfully added to your 
